Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-29Clinical Trial Update: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome [Phase 3]
Phase 3 trial comparing mismatched related donor versus matched unrelated donor stem cell transplantation in pediatric and young adult patie…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in hematologic and myeloproliferative malignancies; study complete…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor [Phase 3]
Phase III study comparing ATG-thymoglobulin vs ATLG-grafalon for GVHD prophylaxis in elderly AML/MDS patients undergoing matched unrelated d…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) [Phase 2]
A phase 2 trial is evaluating adding the IDH2 inhibitor enasidenib to cedazuridine-decitabine therapy for higher-risk myelodysplastic syndro…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
Completed clinical trial evaluating individual molecular measurable residual disease (MRD) monitoring in patients with myelodysplastic syndr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the combination of CPX-351 (liposomal cytarabine and daunorubicin) with Quizartinib for acute myelo…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations [Phase 2]
A Phase 2 clinical trial is investigating allogeneic hematopoietic stem cell transplantation for patients with GATA2 mutations, currently in…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) [Phase 2]
This is a Phase 2 screening trial (MYELOMATCH) sponsored by the National Cancer Institute to assign people with myeloid cancers to a treatme…
-
CLINICAL_TRIALS other · 2026-04-24Clinical Trial Update: Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes [Phase 1]
Phase 1 trial evaluating cirtuvivint alone and in combination with ASTX727 in patients with acute myeloid leukemia and myelodysplastic syndr…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) [Phase 2]
This Phase 2 trial from the University of Manitoba is evaluating antibiotic prophylaxis in patients with myelodysplastic syndrome and acute …
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Biology Studies of Hematologic Cancers
The document reports an NCI-sponsored biology-focused clinical trial update in hematologic cancers, with enrollment by invitation for condit…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) [Phase 1, Phase 2]
A clinical trial update on active myeloid-target compound combinations for myelodysplastic syndromes with myeloproliferative neoplasm overla…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy [Phase 1]
This clinical trial aims to determine the highest tolerated dose of imetelstat when given with fludarabine and cytarabine in children with r…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation [Phase 1, Phase 2]
This clinical trial update reports Phase 1/2 results for Enasidenib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]
Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantat…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of azacitidine and quizartinib for patients with chronic myelomonocytic leukemia, myel…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 1, Phase 2]
This update describes a Phase 1/2 clinical trial evaluating a triplet regimen of azacitidine, venetoclax, and gilteritinib in patients with …
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating a two-step reduced-intensity conditioning approach for bone marrow transplant in adults with hematologic malignanci…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations [Phase 2]
This entry outlines a Phase 2 clinical trial testing olutasidenib in combination with a co-targeted therapy for relapsed or refractory IDH1-…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 trial update evaluating venetoclax with sequential busulfan, cladribine, and fludarabine phosphate as conditioning before donor stem…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA [Phase 2]
A Phase 2 clinical trial compares romiplostim to recombinant human thrombopoietin (rhTPO) for platelet engraftment after transplantation in …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating CD45RA-depleted stem cell addback to prevent viral or fungal infections following TCRab/CD19-deplet…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating a combination of methylprednisolone, horse anti-thymocyte globulin, cyclosporine, and growth factors (filg…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial update. It evaluates a conditioning strategy using chemotherapy, total body irradiation, and post-transpl…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1]
Phase 1 trial of Vyxeos (CPX-351) is investigating treatment of relapsed or refractory high-risk myelodysplastic syndrome and chronic myelom…